{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "5abcb64d",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "239\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import requests\n",
    "from bs4 import BeautifulSoup\n",
    "\n",
    "def extract_url_without_patents(source):\n",
    "    urls = []\n",
    "    for _ in source:\n",
    "        if len(_.split(\"(h\")) > 1:\n",
    "            url = _.split(\"(\")[1]\n",
    "            url = url.split(\")\")[0]\n",
    "            if url not in urls and len(url) != 0 and 'patent' not in url:\n",
    "                urls.append(url)\n",
    "    return urls\n",
    "\n",
    "def extract_url(source):\n",
    "    urls = []\n",
    "    for _ in source:\n",
    "        if len(_.split(\"(h\")) > 1:\n",
    "            url = _.split(\"(\")[1]\n",
    "            url = url.split(\")\")[0]\n",
    "            if url not in urls and len(url) != 0:\n",
    "                urls.append(url)\n",
    "    return urls\n",
    "df = pd.read_csv (r'covabdab.csv')\n",
    "print(len(extract_url(df[\"Sources\"])))\n",
    "list_of_urls = extract_url_without_patents(df[\"Sources\"])\n",
    "with open(\"url.txt\", \"w\") as f:\n",
    "        for name in list_of_urls:\n",
    "            f.write(str(name) + \"\\n\")\n",
    "            "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "189dd6d5",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "df = pd.read_csv('covabdab.csv')\n",
    "papers = []\n",
    "rawlist = []\n",
    "urllist = []\n",
    "for x in set(df['Sources']):\n",
    "    papers.append(x)\n",
    "for s in papers:\n",
    "    rawlist.append(s[s.find(\"(\")+1:s.find(\")\")])\n",
    "for _ in rawlist:\n",
    "    if _ not in urllist and 'patent' not in _ and 'rcsb' not in _:\n",
    "        urllist.append(_)\n",
    "        \n",
    "with open(\"urls.txt\", \"w\") as f:\n",
    "        for name in urllist:\n",
    "            f.write(str(name) + \"\\n\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "7bcb9bc5",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<title>Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex</title>\n"
     ]
    }
   ],
   "source": [
    "from bs4 import BeautifulSoup\n",
    "import requests\n",
    "headers = {'User-Agent': 'Mozilla/5.0 (Windows NT 6.1; WOW64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/56.0.2924.76 Safari/537.36'}\n",
    "page = requests.get(\"https://www.ncbi.nlm.nih.gov/pmc/articles/doi/10.1016/j.ebiom.2021.103748\", headers = headers)\n",
    "soup = BeautifulSoup(page.content, 'html.parser')\n",
    "print(soup.title)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "80f84f48",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "https://www.biorxiv.org/content/10.1101/2021.03.02.433360v1\n",
      "Fragment-based computational design of antibodies targeting structured epitopes | bioRxiv\n",
      "https://cvi.asm.org/content/13/5/594.long\n",
      "Production of an Anti-Severe Acute Respiratory Syndrome (SARS) Coronavirus Human Monoclonal Antibody Fab Fragment by Using a Combinatorial Immunoglobulin Gene Library Derived from Patients Who Recovered from SARS | Clinical and Vaccine Immunology\n",
      "https://www.nature.com/articles/s41586-020-2456-9\n",
      "Convergent antibody responses to SARS-CoV-2 in convalescent individuals | Nature\n",
      "https://www.nature.com/articles/s41467-021-23825-2\n",
      "Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers | Nature Communications\n",
      "https://www.sciencedirect.com/science/article/pii/S1931312821001335\n",
      "Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite - ScienceDirect\n",
      "https://www.pnas.org/content/pnas/112/33/10473.full\n",
      "Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus | PNAS\n",
      "https://www.biorxiv.org/content/10.1101/2021.09.14.460356v1\n",
      "Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display | bioRxiv\n",
      "https://www.nature.com/articles/s41586-020-2571-7\n",
      "Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike | Nature\n",
      "https://www.nature.com/articles/s41594-021-00596-4\n",
      "Structural basis for broad coronavirus neutralization | Nature Structural & Molecular Biology\n",
      "https://www.nature.com/articles/s41422-020-00446-w\n",
      "Structure-based development of human antibody cocktails against SARS-CoV-2 | Cell Research\n",
      "https://science.sciencemag.org/content/early/2021/01/11/science.abe6230\n",
      "Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape\n",
      "https://www.jimmunol.org/content/early/2020/06/23/jimmunol.2000583\n",
      "A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection | The Journal of Immunology\n",
      "https://www.sciencedirect.com/science/article/pii/S1286457907001724\n",
      "Isolation and identification of an scFv antibody against nucleocapsid protein of SARS-CoV - ScienceDirect\n",
      "https://advances.sciencemag.org/content/4/8/eaas9667\n",
      "Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection\n",
      "https://www.biorxiv.org/content/10.1101/2021.02.25.432969v1\n",
      "Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants | bioRxiv\n",
      "https://www.sciencedirect.com/science/article/pii/S0006291X05023417\n",
      "Cross-reactivity of antibody against SARS-coronavirus nucleocapsid protein with IL-11 - ScienceDirect\n",
      "https://www.biorxiv.org/content/10.1101/2020.06.02.129098v2\n",
      "Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody | bioRxiv\n",
      "https://www.nature.com/articles/cr2015113\n",
      "A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein | Cell Research\n",
      "https://www.sciencedirect.com/science/article/pii/S2589004221004478\n",
      "Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice - ScienceDirect\n",
      "https://www.biorxiv.org/content/10.1101/2020.06.30.178897v1\n",
      "A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies | bioRxiv\n",
      "https://academic.oup.com/jid/article/215/12/1807/3786458\n",
      "Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset | The Journal of Infectious Diseases | Oxford Academic\n",
      "https://www.nature.com/articles/s41586-020-2349-y\n",
      "Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody | Nature\n",
      "https://science.sciencemag.org/content/early/2020/06/19/science.abc6952/tab-pdf\n",
      "A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2\n",
      "https://www.biorxiv.org/content/10.1101/2020.08.15.252320v1.full\n",
      "A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model | bioRxiv\n",
      "https://www.nature.com/articles/s41467-020-19204-y\n",
      "Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2 | Nature Communications\n",
      "https://pubs.acs.org/doi/10.1021/acs.analchem.1c00677\n",
      "Single-Domain Antibodies for the Detection of SARS-CoV-2 Nucleocapsid Protein | Analytical Chemistry\n",
      "https://www.nature.com/articles/s41598-021-88809-0\n",
      "Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies | Scientific Reports\n",
      "https://www.biorxiv.org/content/10.1101/2021.05.31.446421v1\n",
      "Accelerated Antibody Discovery Targeting the SARS-CoV-2 Spike Protein for COVID-19 Therapeutic Potential | bioRxiv\n",
      "https://www.nature.com/articles/s41594-021-00652-z\n",
      "Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function | Nature Structural & Molecular Biology\n",
      "https://www.biorxiv.org/content/10.1101/2020.08.19.253369v2.full\n",
      "A rapid and efficient screening system for neutralizing antibodies and its application for the discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD | bioRxiv\n",
      "https://www.science.org/doi/full/10.1126/scitranslmed.abi7826\n",
      "An affinity-enhanced, broadly neutralizing heavy chain–only antibody protects against SARS-CoV-2 infection in animal models\n",
      "https://www.pnas.org/content/114/35/E7348\n",
      "Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen | PNAS\n",
      "https://science.sciencemag.org/content/early/2021/06/30/science.abh1766\n",
      "Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants\n",
      "https://www.biorxiv.org/content/10.1101/2021.03.23.436684v1\n",
      "Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects | bioRxiv\n",
      "https://www.nature.com/articles/s41586-021-03676-z\n",
      "Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants | Nature\n",
      "https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0030237\n",
      "Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants\n",
      "https://www.nature.com/articles/s41591-020-0998-x\n",
      "Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein | Nature Medicine\n",
      "https://www.sciencedirect.com/science/article/pii/S0092867420306206\n",
      "Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells - ScienceDirect\n",
      "https://science.sciencemag.org/content/early/2020/11/04/science.abe4747\n",
      "Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2\n",
      "https://www.biorxiv.org/content/10.1101/2021.05.02.442326v1\n",
      "Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals | bioRxiv\n",
      "https://science.sciencemag.org/content/early/2020/06/15/science.abc7424\n",
      "Broad neutralization of SARS-related viruses by human monoclonal antibodies\n",
      "https://www.nature.com/articles/ncomms8712\n",
      "Evaluation of candidate vaccine approaches for MERS-CoV | Nature Communications\n",
      "https://www.biorxiv.org/content/10.1101/2020.07.09.195263v1\n",
      "Structures of potent and convergent neutralizing antibodies bound to the SARS-CoV-2 spike unveil a unique epitope responsible for exceptional potency | bioRxiv\n",
      "https://www.pnas.org/content/pnas/111/19/E2018.full\n",
      "Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution | PNAS\n",
      "https://www.nature.com/articles/s41467-020-16256-y\n",
      "A human monoclonal antibody blocking SARS-CoV-2 infection | Nature Communications\n",
      "https://www.embopress.org/doi/full/10.15252/embr.202052325\n",
      "NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies | EMBO reports\n",
      "https://www.biorxiv.org/content/10.1101/2020.12.31.424729v1\n",
      "The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates | bioRxiv\n",
      "https://www.sciencedirect.com/science/article/pii/S2211124721000127\n",
      "Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD - ScienceDirect\n",
      "https://stm.sciencemag.org/content/13/577/eabf1555\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Enhanced SARS-CoV-2 neutralization by dimeric IgA\n",
      "https://jvi.asm.org/content/79/3/1635\n",
      "Molecular and Biological Characterization of Human Monoclonal Antibodies Binding to the Spike and Nucleocapsid Proteins of Severe Acute Respiratory Syndrome Coronavirus | Journal of Virology\n",
      "https://www.biorxiv.org/content/10.1101/2020.12.29.424711v1\n",
      "Deep mining of early antibody response in COVID-19 patients yields potent neutralisers and reveals high level of convergence | bioRxiv\n",
      "https://www.biorxiv.org/content/10.1101/2020.10.13.336800v1\n",
      "Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies | bioRxiv\n",
      "https://www.embopress.org/doi/full/10.15252/embj.2021107985\n",
      "Neutralization of SARS‐CoV‐2 by highly potent, hyperthermostable, and mutation‐tolerant nanobodies | The EMBO Journal\n",
      "https://www.sciencedirect.com/science/article/pii/S0022283609003374\n",
      "Structural Insights into Immune Recognition of the Severe Acute Respiratory Syndrome Coronavirus S Protein Receptor Binding Domain - ScienceDirect\n",
      "https://elifesciences.org/articles/64815\n",
      "The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates | eLife\n",
      "https://onlinelibrary.wiley.com/doi/full/10.1002/mco2.79\n",
      "Potent neutralizing RBD‐specific antibody cocktail against SARS‐CoV‐2 and its mutant - Jia - 2021 - MedComm - Wiley Online Library\n",
      "https://www.biorxiv.org/content/10.1101/2020.04.16.045419v2\n",
      "Sybodies targeting the SARS-CoV-2 receptor-binding domain | bioRxiv\n",
      "https://www.biorxiv.org/content/10.1101/2020.04.16.045419v2\n",
      "Sybodies targeting the SARS-CoV-2 receptor-binding domain | bioRxiv\n",
      "https://www.biorxiv.org/content/10.1101/2020.11.10.376822v1\n",
      "Highly potent bispecific sybodies neutralize SARS-CoV-2 | bioRxiv\n",
      "https://www.sciencedirect.com/science/article/pii/S0165242707000487\n",
      "A dominant antigenic epitope on SARS-CoV spike protein identified by an avian single-chain variable fragment (scFv)-expressing phage - ScienceDirect\n",
      "https://www.biorxiv.org/content/10.1101/2020.11.11.378778v1\n",
      "Rapid generation of potent antibodies by autonomous hypermutation in yeast | bioRxiv\n",
      "https://www.biorxiv.org/content/10.1101/2021.09.30.462420v1.full\n",
      "SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies | bioRxiv\n",
      "https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1000197\n",
      "Broadening of Neutralization Activity to Directly Block a Dominant Antibody-Driven SARS-Coronavirus Evolution Pathway\n",
      "https://www.cell.com/cell/fulltext/S0092-8674(20)31234-4\n",
      "Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology: Cell\n",
      "https://www.nature.com/articles/s41467-021-25153-x#Sec34\n",
      "Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics | Nature Communications\n",
      "https://academic.oup.com/jid/article/218/8/1249/5017222\n",
      "Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient | The Journal of Infectious Diseases | Oxford Academic\n",
      "https://science.sciencemag.org/content/early/2020/06/15/science.abc5902\n",
      "Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability\n",
      "https://www.biorxiv.org/content/10.1101/2020.05.12.091298v1\n",
      "Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual | bioRxiv\n",
      "https://www.biorxiv.org/content/10.1101/2021.06.02.446813v1\n",
      "Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking | bioRxiv\n",
      "https://science.sciencemag.org/content/early/2021/06/30/science.abi7994\n",
      "SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern\n",
      "https://www.sciencedirect.com/science/article/pii/S0092867421008849\n",
      "Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike - ScienceDirect\n",
      "https://www.biorxiv.org/content/10.1101/2021.01.26.428356v1\n",
      "Sequence signatures of two IGHV3-53/3-66 public clonotypes to SARS-CoV-2 receptor binding domain | bioRxiv\n",
      "https://www.cell.com/cell-reports/fulltext/S2211-1247(21)00264-3\n",
      "Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class: Cell Reports\n",
      "https://www.sciencedirect.com/science/article/pii/S0092867421005353\n",
      "B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV - ScienceDirect\n",
      "https://www.sciencedirect.com/science/article/pii/S009286742100221X\n",
      "The antigenic anatomy of SARS-CoV-2 receptor binding domain - ScienceDirect\n",
      "https://www.biorxiv.org/content/10.1101/2021.05.29.443900v1\n",
      "Broadening a SARS-CoV-1 neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution | bioRxiv\n",
      "https://www.nature.com/articles/s41421-021-00295-w\n",
      "Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries | Cell Discovery\n",
      "https://www.biorxiv.org/content/10.1101/2021.07.20.453054v1\n",
      "Discovery of nanobodies against SARS-CoV-2 and an uncommon neutralizing mechanism | bioRxiv\n",
      "https://science.sciencemag.org/content/early/2020/09/23/science.abe3354\n",
      "Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms\n",
      "https://www.biorxiv.org/content/10.1101/2021.07.08.451649v1\n",
      "Structure of a germline-like human antibody defines a neutralizing epitope on the SARS-CoV-2 spike NTD | bioRxiv\n",
      "https://science.sciencemag.org/content/early/2021/08/03/science.abj3321\n",
      "Broad betacoronavirus neutralization by a stem helix–specific human antibody\n",
      "https://science.sciencemag.org/content/early/2020/05/12/science.abc2241\n",
      "A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2\n",
      "https://www.biorxiv.org/content/10.1101/2020.12.09.417741v1\n",
      "Characterization of protease activity of Nsp3 from SARS-CoV-2 and its in vitro inhibition by nanobodies | bioRxiv\n",
      "https://www.nature.com/articles/s41467-020-18387-8\n",
      "Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain | Nature Communications\n",
      "https://www.biorxiv.org/content/10.1101/2021.07.05.451203v1\n",
      "Mouse Antibodies with Activity Against the SARS-CoV-2 D614G and B.1.351 Variants | bioRxiv\n",
      "https://www.biorxiv.org/content/10.1101/2020.09.03.280370v1.full\n",
      "Development of SARS-CoV-2 Nucleocapsid Specific Monoclonal Antibodies | bioRxiv\n",
      "https://science.sciencemag.org/content/early/2020/06/15/science.abc7520\n",
      "Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model\n",
      "https://www.sciencedirect.com/science/article/pii/S2211124721004435\n",
      "Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2 - ScienceDirect\n",
      "https://www.sciencedirect.com/science/article/pii/S2211124721012869\n",
      "Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain - ScienceDirect\n",
      "https://www.jbc.org/content/281/45/34610.long\n",
      "Structural Basis of Neutralization by a Human Anti-severe Acute Respiratory Syndrome Spike Protein Antibody, 80R* - Journal of Biological Chemistry\n",
      "https://www.biorxiv.org/content/10.1101/2021.04.19.440481v1\n",
      "Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants | bioRxiv\n",
      "https://pubmed.ncbi.nlm.nih.gov/34508662/\n",
      "A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site - PubMed\n",
      "https://www.biorxiv.org/content/10.1101/2021.01.03.425141v1\n",
      "Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry | bioRxiv\n",
      "https://www.nature.com/articles/s41421-021-00292-z\n",
      "Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants | Cell Discovery\n",
      "https://www.biorxiv.org/content/10.1101/2020.12.31.424987v1\n",
      "Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses | bioRxiv\n",
      "https://www.nature.com/articles/s41586-021-03696-9\n",
      "Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection | Nature\n",
      "https://www.sciencedirect.com/science/article/pii/S1074761321001357\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant - ScienceDirect\n",
      "https://www.nature.com/articles/s41423-020-0426-7\n",
      "Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor | Cellular & Molecular Immunology\n",
      "https://www.biorxiv.org/content/10.1101/2021.04.30.442182v3\n",
      "LY-CoV1404 potently neutralizes SARS-CoV-2 variants | bioRxiv\n",
      "https://www.nature.com/articles/s41586-021-03324-6\n",
      "mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants | Nature\n",
      "https://doi.org/10.1016/j.cell.2020.06.044\n",
      "Redirecting\n",
      "https://www.biorxiv.org/content/10.1101/2021.04.26.441501v1\n",
      "A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope | bioRxiv\n",
      "https://www.cell.com/cell-reports/fulltext/S2211-1247(19)31100-3\n",
      "Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD: Cell Reports\n",
      "https://www.biorxiv.org/content/10.1101/2020.11.24.395079v1\n",
      "A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro | bioRxiv\n",
      "https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009165\n",
      "Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors\n",
      "https://www.biorxiv.org/content/10.1101/2021.02.12.430940v1\n",
      "Single-cell sequencing of plasma cells from COVID-19 patients reveals highly expanded clonal lineages produce specific and neutralizing antibodies to SARS-CoV-2 | bioRxiv\n",
      "https://www.nature.com/articles/s41467-021-23074-3#Sec18\n",
      "Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection | Nature Communications\n",
      "https://www.biorxiv.org/content/10.1101/2021.05.16.444004v1\n",
      "Potent neutralization of SARS-CoV-2 variants of concern by an antibody with a unique genetic signature and structural mode of spike recognition | bioRxiv\n",
      "https://www.sciencedirect.com/science/article/pii/S0006291X05002263\n",
      "Identification of single-chain antibody fragments specific against SARS-associated coronavirus from phage-displayed antibody library - ScienceDirect\n",
      "https://www.pnas.org/content/112/28/8738\n",
      "Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection | PNAS\n",
      "https://www.semanticscholar.org/paper/A-human-neutralizing-antibody-against-a-epitope-by-Duan-Ji/ca990dfe192853fc9fc107398352b16a5c45d39b/figure/2\n",
      "Figure 2 from 645 Duan.qxp | Semantic Scholar\n",
      "https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1002859\n",
      "Structural Bases of Coronavirus Attachment to Host Aminopeptidase N and Its Inhibition by Neutralizing Antibodies\n",
      "https://www.cell.com/cell/fulltext/S0092-8674(21)00221-X\n",
      "The antigenic anatomy of SARS-CoV-2 receptor binding domain: Cell\n",
      "https://www.nature.com/articles/s41422-020-00444-y\n",
      "Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection | Cell Research\n",
      "https://www.nature.com/articles/s41586-020-2381-y\n",
      "A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 | Nature\n",
      "https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3001209\n",
      "Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes\n",
      "https://www.researchsquare.com/article/rs-105739/v1\n",
      "Development of Multivalent Nanobodies Blocking SARS CoV 2 Infection by Targeting RBD of Spike Protein | Research Square\n",
      "https://www.biorxiv.org/content/10.1101/2020.06.09.143438v1\n",
      "Potent synthetic nanobodies against SARS-CoV-2 and molecular basis for neutralization | bioRxiv\n",
      "https://www.biorxiv.org/content/10.1101/2021.04.07.438818v1\n",
      "Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody | bioRxiv\n",
      "https://www.biorxiv.org/content/10.1101/2021.06.04.447066v1\n",
      "Human single-chain antibodies neutralize SARS-CoV-2 variants by engaging an essential epitope of the spike: a new weapon against COVID-19 | bioRxiv\n",
      "https://www.pnas.org/content/117/47/29832\n",
      "Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection | PNAS\n",
      "https://www.biorxiv.org/content/10.1101/2020.05.13.092619v2\n",
      "Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals | bioRxiv\n",
      "https://www.cell.com/cell-reports/fulltext/S2211-1247(18)30951-3\n",
      "Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein: Cell Reports\n",
      "https://doi.org/10.1016/j.cell.2021.03.028\n",
      "Redirecting\n",
      "https://www.nature.com/articles/s41586-021-03807-6\n",
      "SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape | Nature\n",
      "https://academic.oup.com/nsr/article/8/3/nwaa297/6041739\n",
      "Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2 | National Science Review | Oxford Academic\n",
      "https://www.nature.com/articles/s41467-020-18159-4\n",
      "A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes | Nature Communications\n",
      "https://www.biorxiv.org/content/10.1101/2020.06.09.137935v1\n",
      "Fast isolation of sub-nanomolar affinity alpaca nanobody against the Spike RBD of SARS-CoV-2 by combining bacterial display and a simple single-step density gradient selection | bioRxiv\n",
      "https://www.sciencedirect.com/science/article/pii/S2666379121001567\n",
      "Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions - ScienceDirect\n",
      "https://www.biorxiv.org/content/10.1101/2020.08.09.242867v1.full\n",
      "A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential | bioRxiv\n",
      "https://www.nature.com/articles/s41422-021-00514-9\n",
      "Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines | Cell Research\n",
      "https://jvi.asm.org/content/92/10/e02002-17\n",
      "Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape | Journal of Virology\n",
      "https://www.jbc.org/article/S0021-9258(21\n",
      "na\n",
      "https://cvi.asm.org/content/13/8/953\n",
      "Human Neutralizing Fab Molecules against Severe Acute Respiratory Syndrome Coronavirus Generated by Phage Display | Clinical and Vaccine Immunology\n",
      "https://www.jbc.org/content/295/36/12814.full\n",
      "Identification of an anti–SARS–CoV-2 receptor-binding domain–directed human monoclonal antibody from a naïve semisynthetic library - Journal of Biological Chemistry\n",
      "https://www.nature.com/articles/ncomms9223\n",
      "Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody | Nature Communications\n",
      "https://www.biorxiv.org/content/10.1101/2020.11.06.370676v1\n",
      "Potent SARS-CoV-2 neutralizing antibodies selected from a human antibody library constructed decades ago | bioRxiv\n",
      "https://stm.sciencemag.org/content/6/234/234ra59.long\n",
      "Potent Neutralization of MERS-CoV by Human Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein\n",
      "https://doi.org/10.1021/acssynbio.0c00566\n",
      "Toolkit for Quickly Generating and Characterizing Molecular Probes Specific for SARS-CoV-2 Nucleocapsid as a Primer for Future Coronavirus Pandemic Preparedness | ACS Synthetic Biology\n",
      "https://www.biorxiv.org/content/10.1101/2021.04.16.440101v1\n",
      "A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model | bioRxiv\n",
      "https://www.nature.com/articles/s41594-020-0469-6\n",
      "Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2 | Nature Structural & Molecular Biology\n",
      "https://www.nature.com/articles/s41467-019-10897-4\n",
      "Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein | Nature Communications\n",
      "https://advances.sciencemag.org/content/early/2021/04/22/sciadv.abg7607\n",
      "SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity\n",
      "https://www.tandfonline.com/doi/full/10.1080/19420862.2021.1922134\n",
      "Full article: Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies\n",
      "https://science.sciencemag.org/content/early/2020/06/15/science.abd0827\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail\n",
      "https://www.nature.com/articles/s41586-021-03738-2\n",
      "SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses | Nature\n",
      "https://www.sciencedirect.com/science/article/pii/S0006291X05010892\n",
      "A human SARS-CoV neutralizing antibody against epitope on S2 protein - ScienceDirect\n",
      "https://www.nature.com/articles/s41467-021-24514-w\n",
      "Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2 | Nature Communications\n",
      "https://www.jbc.org/content/281/23/15829.long\n",
      "Structure of Severe Acute Respiratory Syndrome Coronavirus Receptor-binding Domain Complexed with Neutralizing Antibody* - Journal of Biological Chemistry\n",
      "https://www.biorxiv.org/content/10.1101/2021.01.07.425806v1\n",
      "Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library | bioRxiv\n",
      "https://www.nature.com/articles/s41586-021-03207-w\n",
      "Evolution of antibody immunity to SARS-CoV-2 | Nature\n",
      "https://www.nature.com/articles/s41422-021-00555-0\n",
      "Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants | Cell Research\n",
      "https://www.nature.com/articles/s41586-021-03817-4\n",
      "Broad sarbecovirus neutralization by a human monoclonal antibody | Nature\n",
      "https://www.nature.com/articles/s41598-020-79036-0\n",
      "High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme | Scientific Reports\n",
      "https://www.biorxiv.org/content/10.1101/2021.02.08.429275v1\n",
      "A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration | bioRxiv\n",
      "https://www.sciencedirect.com/science/article/pii/S2451945621002646\n",
      "Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis - ScienceDirect\n",
      "https://www.biorxiv.org/content/10.1101/2020.08.08.242511v1.full\n",
      "Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike | bioRxiv\n",
      "https://www.biorxiv.org/content/10.1101/2021.04.01.437942v1\n",
      "Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants | bioRxiv\n",
      "https://www.nature.com/articles/s42003-021-02029-w\n",
      "Structure and function analysis of a potent human neutralizing antibody CA521FALA against SARS-CoV-2 | Communications Biology\n",
      "https://www.sciencedirect.com/science/article/pii/S0042682206006854\n",
      "Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse® - ScienceDirect\n",
      "https://www.biorxiv.org/content/10.1101/2021.02.02.429458v1\n",
      "Naive human B cells can neutralize SARS-CoV-2 through recognition of its receptor binding domain | bioRxiv\n",
      "https://www.sciencedirect.com/science/article/pii/S0092867421002245\n",
      "Extremely potent human monoclonal antibodies from COVID-19 convalescent patients - ScienceDirect\n",
      "https://www.sciencedirect.com/science/article/pii/S0006291X11022984\n",
      "Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and design of vaccine immunogens - ScienceDirect\n",
      "https://www.sciencedirect.com/science/article/pii/S0092867420304943\n",
      "Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies - ScienceDirect\n",
      "https://www.biorxiv.org/content/10.1101/2020.11.13.381533v1\n",
      "Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2 | bioRxiv\n",
      "https://academic.oup.com/jid/article/193/5/685/877553\n",
      "Therapy with a Severe Acute Respiratory Syndrome–Associated Coronavirus–Neutralizing Human Monoclonal Antibody Reduces Disease Severity and Viral Burden in Golden Syrian Hamsters | The Journal of Infectious Diseases | Oxford Academic\n",
      "https://www.nature.com/articles/s41586-020-2380-z\n",
      "Human neutralizing antibodies elicited by SARS-CoV-2 infection | Nature\n",
      "https://www.sciencedirect.com/science/article/pii/S2211124720308998\n",
      "Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection - ScienceDirect\n",
      "https://science.sciencemag.org/content/early/2020/11/04/science.abe3255\n",
      "An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike\n",
      "https://www.biorxiv.org/content/10.1101/2020.06.12.148387v1\n",
      "Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient | bioRxiv\n",
      "https://www.pnas.org/content/118/19/e2101918118\n",
      "Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice | PNAS\n",
      "https://science.sciencemag.org/content/early/2021/05/03/science.abg5268\n",
      "Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes\n",
      "https://www.biorxiv.org/content/10.1101/2020.09.30.318972v1\n",
      "LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection | bioRxiv\n",
      "https://www.nature.com/articles/s41467-021-21609-2\n",
      "SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface | Nature Communications\n",
      "https://www.researchsquare.com/article/rs-548968/v1\n",
      "A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19 | Research Square\n",
      "https://www.nature.com/articles/s41467-020-18174-5\n",
      "An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction | Nature Communications\n",
      "https://onlinelibrary.wiley.com/doi/10.1002/mco2.60\n",
      "A potent neutralizing nanobody against SARS‐CoV‐2 with inhaled delivery potential - Gai - 2021 - MedComm - Wiley Online Library\n",
      "https://www.sciencedirect.com/science/article/pii/S0161589004002548\n",
      "Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus - ScienceDirect\n",
      "https://www.sciencedirect.com/science/article/pii/S0092867421004281\n",
      "Antibody evasion by the P.1 strain of SARS-CoV-2 - ScienceDirect\n",
      "https://www.sciencedirect.com/science/article/pii/S0166093407002236\n",
      "Chicken single-chain variable fragments against the SARS-CoV spike protein - ScienceDirect\n",
      "https://www.biorxiv.org/content/10.1101/2021.04.07.438849v2\n",
      "Synthetic repertoires derived from convalescent COVID-19 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary binding modality | bioRxiv\n",
      "https://jvi.asm.org/content/88/14/7796\n",
      "Exceptionally Potent Neutralization of Middle East Respiratory Syndrome Coronavirus by Human Monoclonal Antibodies | Journal of Virology\n",
      "https://www.nature.com/articles/s41467-021-22926-2\n",
      "A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes | Nature Communications\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import requests\n",
    "from bs4 import BeautifulSoup\n",
    "def get_title_from_url(list):\n",
    "    results = []\n",
    "    for _ in list:\n",
    "        print(_)\n",
    "        headers = {'User-Agent': 'Mozilla/5.0 (X11; Ubuntu; Linux x86_64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/55.0.2919.83 Safari/537.36'}\n",
    "        r = requests.get(_ , headers=headers)\n",
    "        soup = BeautifulSoup(r.content, 'html.parser')\n",
    "        if soup.title != None:\n",
    "            results.append(soup.title.string)\n",
    "            print(soup.title.string)\n",
    "        else:\n",
    "            results.append('na')\n",
    "            print('na')\n",
    "    return results\n",
    "with open('urls.txt') as f:\n",
    "    urls = f.read().splitlines()\n",
    "titles = get_title_from_url(urls)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "3124d23f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "183\n"
     ]
    }
   ],
   "source": [
    "\n",
    "title = []\n",
    "for t in titles:\n",
    "    t = t.split(\" - S\")[0]\n",
    "    t = t.split(\" | \")[0]\n",
    "    t = t.split(\": C\")[0]\n",
    "    title.append(t)\n",
    "with open(\"titles_edited1.txt\", \"w\") as f:\n",
    "        for name in title:\n",
    "            f.write(str(name) + \".\" + \"\\n\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "id": "87438359",
   "metadata": {},
   "outputs": [],
   "source": [
    "with open('titles.txt') as f:\n",
    "    titles = f.read().splitlines()\n",
    "    \n",
    "title = []\n",
    "for t in titles:\n",
    "    t = t.split(\" - S\")[0]\n",
    "    t = t.split(\" | \")[0]\n",
    "    t = t.split(\": C\")[0]\n",
    "    title.append(t)\n",
    "with open(\"titles_edited.txt\", \"w\") as f:\n",
    "        for name in title:\n",
    "            f.write(str(name) + \".\" + \"\\n\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "caafc87a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "126\n",
      "['ultrapotent sars-cov-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants.', 'generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against sars coronavirus using xenomouse®.', 'therapy with a severe acute respiratory syndrome–associated coronavirus–neutralizing human monoclonal antibody reduces disease severity and viral burden in golden syrian hamsters.', 'potent neutralization of sars-cov-2 variants of concern by an antibody with a unique genetic signature and structural mode of spike recognition.', 'a monoclonal antibody against staphylococcal enterotoxin b superantigen inhibits sars-cov-2 entry in vitro.', 'structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80r*.', 'naive human b cells can neutralize sars-cov-2 through recognition of its receptor binding domain.', 'a rapid and efficient screening system for neutralizing antibodies and its application for the discovery of potent neutralizing antibodies to sars-cov-2 s-rbd.', 'production of an anti-severe acute respiratory syndrome (sars) coronavirus human monoclonal antibody fab fragment by using a combinatorial immunoglobulin gene library derived from patients who recovered from sars.', 'mouse antibodies with activity against the sars-cov-2 d614g and b.1.351 variants.', 'structures of potent and convergent neutralizing antibodies bound to the sars-cov-2 spike unveil a unique epitope responsible for exceptional potency.', 'potent neutralizing antibodies against sars-cov-2 identified by high-throughput single-cell sequencing of convalescent patients’ b cells.', 'structure and function analysis of a potent human neutralizing antibody ca521fala against sars-cov-2.', 'full article: potent sars-cov-2 binding and neutralization through maturation of iconic sars-cov-1 antibodies.', 'sars-cov-2 beta variant infection elicits potent lineage-specific and cross-reactive antibodies.', 'fragment-based computational design of antibodies targeting structured epitopes.', 'discovery of nanobodies against sars-cov-2 and an uncommon neutralizing mechanism.', 'broadening a sars-cov-1 neutralizing antibody for potent sars-cov-2 neutralization through directed evolution.', 'single-cell sequencing of plasma cells from covid-19 patients reveals highly expanded clonal lineages produce specific and neutralizing antibodies to sars-cov-2.', 'a potent neutralizing nanobody against sars‐cov‐2 with inhaled delivery potential.', 'identification of an anti–sars–cov-2 receptor-binding domain–directed human monoclonal antibody from a naïve semisynthetic library.', 'deep mining of early antibody response in covid-19 patients yields potent neutralisers and reveals high level of convergence.', 'cross-reactivity of antibody against sars-coronavirus nucleocapsid protein with il-11.', 'potent synthetic nanobodies against sars-cov-2 and molecular basis for neutralization.', 'chicken single-chain variable fragments against the sars-cov spike protein.', 'structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody*.', 'potent neutralizing rbd‐specific antibody cocktail against sars‐cov‐2 and its mutant.', 'human single-chain antibodies neutralize sars-cov-2 variants by engaging an essential epitope of the spike: a new weapon against covid-19.', 'isolation and identification of an scfv antibody against nucleocapsid protein of sars-cov.', 'the development of nanosota-1 as anti-sars-cov-2 nanobody drug candidates.', 'characterization of protease activity of nsp3 from sars-cov-2 and its in vitro inhibition by nanobodies.', 'neutrobodyplex—monitoring sars‐cov‐2 neutralizing immune responses using nanobodies.', 'broad betacoronavirus neutralization by a stem helix–specific human antibody.', 'structure of a germline-like human antibody defines a neutralizing epitope on the sars-cov-2 spike ntd.', 'development of multivalent nanobodies blocking sars cov 2 infection by targeting rbd of spike protein.', 'neutralization of sars‐cov‐2 by highly potent, hyperthermostable, and mutation‐tolerant nanobodies.', 'potent sars-cov-2 neutralizing antibodies selected from a human antibody library constructed decades ago.', 'sybodies targeting the sars-cov-2 receptor-binding domain.', 'efficient discovery of potently neutralizing sars-cov-2 antibodies using libra-seq with ligand blocking.', 'a pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a sars-cov-2 infection model.', 'bi-paratopic and multivalent human vh domains neutralize sars-cov-2 by targeting distinct epitopes within the ace2 binding interface of spike.', 'fast isolation of sub-nanomolar affinity alpaca nanobody against the spike rbd of sars-cov-2 by combining bacterial display and a simple single-step density gradient selection.', 'enhanced sars-cov-2 neutralization by dimeric iga.']\n"
     ]
    }
   ],
   "source": [
    "with open('titles_edited1.txt') as f:\n",
    "    titles_covab = f.read().splitlines()\n",
    "    \n",
    "with open('pubmed_results.txt') as f:\n",
    "    titles_search = f.read().splitlines()\n",
    "\n",
    "titles_covab_l = [elem.lower() for elem in titles_covab]   \n",
    "titles_search_l = [elem.lower() for elem in titles_search] \n",
    "not_searched = [] \n",
    "yes = 0\n",
    "for elem in titles_covab_l:\n",
    "    if elem.replace('sars-cov-2','sars-cov-2') not in titles_search_l:\n",
    "        not_searched.append(elem)\n",
    "    else:\n",
    "        yes += 1\n",
    "print(yes)\n",
    "print(not_searched)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "1c6db466",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "eb2faae7",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.7"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
